Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 91, Issue 1, Pages 30-43Publisher
WILEY
DOI: 10.1038/clpt.2011.278
Keywords
-
Categories
Funding
- Arthritis Research UK
- Medical Research Council
- National Institute for Health Research
- National Institute for Health Research [NF-SI-0507-10104, 06/303/84] Funding Source: researchfish
Ask authors/readers for more resources
Rheumatoid arthritis (RA) remains a major clinical problem, but treatments involving biologics have revolutionized its management. They target pathogenically relevant cytokines such as tumor necrosis factor and immune cells such as B cells. In RA, biologics reduce joint inflammation, limit erosive damage, decrease disability, and improve quality of life. Infections are the main risk associated with their use. Because of the high prices of biologics, their cost-effectiveness is a matter of debate. They are mainly coadministered with disease-modifying drugs such as methotrexate when the latter are found to achieve insufficient disease control on their own.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available